For the quarter ended March 2025, Pacific Biosciences of California (PACB) reported revenue of $37.15 million, down 4.3% over the same period last year. EPS came in at -$0.15, compared to -$0.26 in the year-ago quarter.
The reported revenue represents a surprise of +6.15% over the Zacks Consensus Estimate of $35 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +21.05%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Pacific Biosciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product- Instrument: $11 million versus $12.21 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -42.1% change.
- Revenue- Product: $31.11 million versus $30.90 million estimated by three analysts on average.
- Revenue- Service and other: $6.04 million versus $4.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +58.9% change.
- Revenue- Product- Consumable: $20.10 million compared to the $18.69 million average estimate based on three analysts. The reported number represents a change of +25.6% year over year.
View all Key Company Metrics for Pacific Biosciences here>>>
Shares of Pacific Biosciences have returned -22.1% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
